ADAMTS9 and neoplasm: To evaluate the ability of ADAMTS9-AS2 to impact TNBC progression in vivo, we next transduced MDA-MB-231 cells with LV-NC or LV-ADAMTS9-AS2 and then implanted these tumor cells subcutaneously in mice.